TLR3 Human shRNA Lentiviral Particle (Locus ID 7098)

CAT#: TL320554V

TLR3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL320554A virus into HEK293 cells. TL320554A virus was prepared using lenti-shRNA TL320554A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL320554B virus into HEK293 cells. TL320554B virus was prepared using lenti-shRNA TL320554B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL320554C] virus into HEK293 cells. [TL320554C] virus was prepared using lenti-shRNA [TL320554C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL320554D] virus into HEK293 cells. [TL320554D] virus was prepared using lenti-shRNA [TL320554D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 7098
• Synonyms: CD283; IIAE2
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_003265, NM_003265.1, NM_003265.2, BC094737, BC094737.1, BC017954, BC043204, BC059372, BC068487, BC096333, BC096334, BC096335, NM_003265.3
• UniProt ID: O15455
• Summary: The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. This receptor is most abundantly expressed in placenta and pancreas, and is restricted to the dendritic subpopulation of the leukocytes. It recognizes dsRNA associated with viral infection, and induces the activation of NF-kappaB and the production of type I interferons. It may thus play a role in host defense against viruses. Use of alternative polyadenylation sites to generate different length transcripts has been noted for this gene. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).